Corcept Therapeutics | CORT - Pre Tax Profit


Corcept Therapeutics reported $9.91M in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 3.98M 22.34M Mar/2026
Alaunos Therapeutics USD -7.84M 633K Dec/2023
ANI Pharmaceuticals USD 31.48M 18.04M Dec/2025
Ardelyx USD -400K 467K Dec/2025
Assertio Holdings USD -2.88M 648K Sep/2024
Aurora Cannabis CAD -1.58M 48.55M Dec/2025
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Bristol-Myers Squibb USD 1.47B 1.64B Dec/2025
Canopy Growth CAD -62.26M 60.84M Dec/2025
Corcept Therapeutics USD 9.91M 5.33M Dec/2025
Eli Lilly USD 8.27B 1.03B Dec/2025
Esperion Therapeutics USD 63.67M 95M Dec/2025
J&J USD 7.82B 2.86B Mar/2026
Knight Therapeutics CAD -1.92M 13.69M Sep/2025
Lexicon Pharmaceuticals USD -12.77M 16.02M Sep/2025
Merck USD 3.42B 3.32B Dec/2025
Nektar Therapeutics USD -34.7M 2.35M Dec/2025
Novartis USD 3.84B 802M Mar/2026
Novartis USD 5.17B 637M Sep/2025
Omeros USD -65.12M 21.27M Jun/2024
Pacira USD 571K 8.95M Dec/2025
Pfizer USD 5.18B 6.82B Mar/2026
Supernus Pharmaceuticals USD -5.95M 4.04M Mar/2026
TG Therapeutics USD 20.36M 24.73M Mar/2026